{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:06:52Z","timestamp":1772244412895,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioinform."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Identifying disease\u2013target associations is a pivotal step in drug discovery, offering insights that guide the development and optimization of therapeutic interventions. Clinical trial data serves as a valuable source for inferring these associations. However, issues such as inconsistent data quality and limited interpretability pose significant challenges. To overcome these limitations, an integrated approach is required that consolidates evidence from diverse data sources to support the effective prioritization of biological targets for further research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a comprehensive data integration and visualization pipeline to infer and evaluate associations between diseases and known and potential drug targets. This pipeline integrates clinical trial data with standardized metadata, providing an analytical workflow that enables the exploration of diseases linked to specific drug targets as well as facilitating the discovery of drug targets associated with specific diseases. The pipeline employs robust aggregation techniques to consolidate multivariate evidence from multiple studies, leveraging harmonized datasets to ensure consistency and reliability. Disease\u2013target associations are systematically ranked and filtered using a rational scoring framework that assigns confidence scores derived from aggregated statistical metrics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our pipeline evaluates disease\u2013target associations by linking protein-coding genes to diseases and incorporates a confidence assessment method based on aggregated evidence. Metrics such as meanRank scores are employed to prioritize associations, enabling researchers to focus on the most promising hypotheses. This systematic approach streamlines the identification and prioritization of biological targets, enhancing hypothesis generation and evidence-based decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This innovative pipeline provides a scalable solution for hypothesis generation, scoring, and ranking in drug discovery. As an open-source tool, it is equipped with publicly available datasets and designed for ease of use by researchers. The platform empowers scientists to make data-driven decisions in the prioritization of biological targets, facilitating the discovery of novel therapeutic opportunities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fbinf.2025.1579865","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T01:24:07Z","timestamp":1749432247000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["TICTAC: target illumination clinical trial analytics with cheminformatics"],"prefix":"10.3389","volume":"5","author":[{"given":"Jeremiah I.","family":"Abok","sequence":"first","affiliation":[]},{"given":"Jeremy S.","family":"Edwards","sequence":"additional","affiliation":[]},{"given":"Jeremy J.","family":"Yang","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"52138","DOI":"10.1109\/ACCESS.2018.2870052","article-title":"Peeking inside the black-box: a survey on explainable artificial intelligence (XAI)","volume":"6","author":"Adadi","year":"2018","journal-title":"IEEE Access"},{"key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/S43441-020-00206-3","article-title":"Methods for employing information about uncertainty of ascertainment of events in clinical trials","volume":"55","author":"Chen","year":"2020","journal-title":"Ther. Innovation and Regul. Sci."},{"key":"B4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4939-9089-4_5","article-title":"A guide to dictionary-based text mining","volume-title":"Bioinformatics and drug discovery","author":"Cook","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrd4578","article-title":"Mitigating risk in academic preclinical drug discovery","volume":"14","author":"Dahlin","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/s0140-6736(19)33220-9","article-title":"Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study","volume":"395","author":"DeVito","year":"2020","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/J.ZEFQ.2008.06.015","article-title":"Ambiguity of study population analysis and reporting in asthma clinical trials","volume":"102","author":"Frampton","year":"2008","journal-title":"Z. f\u00fcr Evidenz, Fortbild. Qual. im Gesundheitswes."},{"key":"B8","doi-asserted-by":"publisher","first-page":"D1311","DOI":"10.1093\/nar\/gkaa840","article-title":"Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics","volume":"49","author":"Ghoussaini","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-023-01816-5","article-title":"Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms","volume":"22","author":"Huang","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"80ps16","DOI":"10.1126\/scitranslmed.3001862","article-title":"The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics","volume":"3","author":"Huang","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","article-title":"PubChem in 2021: new data content and improved web interfaces","volume":"49","author":"Kim","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jash.2016.01.009","article-title":"Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: p athophysiological hypothesis","volume":"10","author":"Kimura","year":"2016","journal-title":"J. Am. Soc. Hypertens. JASH"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1056\/nejme078110","article-title":"Clinical trial registration: looking back and moving ahead","volume":"356","author":"Laine","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"800","DOI":"10.2337\/db20-0921","article-title":"SGLT2 inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 diabetes: a randomized double-blind, placebo-controlled crossover trial","volume":"70","author":"Lauritsen","year":"2021","journal-title":"Diabetes"},{"key":"B16","first-page":"161","article-title":"Drug candidates derailed in case of mistaken identity","volume":"480","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"B17","first-page":"1239","article-title":"Predicting the clinical outcomes of phase II\/III trials for cancer drugs using the drug's mechanism of action: a database analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1758-2946-7-S1-S5","article-title":"LeadMine: a grammar and dictionary driven approach to entity recognition","volume":"7","author":"Lowe","year":"2015","journal-title":"J. Cheminformatics"},{"key":"B20","first-page":"533","article-title":"Using UMLS Concept unique identifiers (CUIs) for word sense disambiguation in the biomedical domain","volume":"2007","author":"McInnes","year":"2007","journal-title":"AMIA Annu. Symp. Proc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2017.111","article-title":"Opportunities and challenges in phenotypic drug discovery: an industry perspective","volume":"16","author":"Moffat","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd3801","article-title":"The determination and interpretation of the therapeutic index in drug development","volume":"11","author":"Muller","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B23","unstructured":"Illuminating the druggable genome (IDG)\n          \n          \n          2024"},{"key":"B24","doi-asserted-by":"publisher","first-page":"D995","DOI":"10.1093\/nar\/gkw1072","article-title":"Pharos: collating protein information to shed light on the druggable genome","volume":"45","author":"Nguyen","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-1-4939-7357-6_11","article-title":"Challenges and opportunities in enabling high-throughput, miniaturized high content screening","volume":"1683","author":"Nickischer","year":"2018","journal-title":"Methods in molecular biology (Clifton, N.J.)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"D1302","DOI":"10.1093\/nar\/gkaa1027","article-title":"Open Targets Platform: supporting systematic drug\u2013target identification and prioritisation","volume":"49","author":"Ochoa","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrd.2018.14","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1609\/aaai.v26i1.8332","article-title":"Identifying Adverse Drug Events by Relational Learning","volume":"26","author":"Page","year":"2021","journal-title":"Proceedings of the AAAI Conference on Artificial Intelligence"},{"key":"B27","doi-asserted-by":"publisher","first-page":"d7373","DOI":"10.1136\/bmj.d7373","article-title":"Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study","volume":"344","author":"Prayle","year":"2012","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1001566","DOI":"10.1371\/journal.pmed.1001566","article-title":"Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals","volume":"10","author":"Riveros","year":"2013","journal-title":"PLoS Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"D1255","DOI":"10.1093\/nar\/gkab1063","article-title":"The human disease ontology 2022 update","volume":"50","author":"Schriml","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1126\/science.368.6492.693","article-title":"Pandemic could add noise to clinical trial data","volume":"368","author":"Servick","year":"2020","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"D1334","DOI":"10.1093\/nar\/gkaa993","article-title":"TCRD and Pharos 2021: mining the human proteome for disease biology","volume":"49","author":"Sheils","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e33677","DOI":"10.1371\/journal.pone.0033677","article-title":"The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty","volume":"7","author":"Tasneem","year":"2012","journal-title":"PLoS ONE"},{"key":"B35","doi-asserted-by":"publisher","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","article-title":"UniProt: the universal protein Knowledgebase in 2023","volume":"51","author":"Bateman","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"k1452","DOI":"10.1136\/bmj.k1452","article-title":"How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider","volume":"361","author":"Tse","year":"2018","journal-title":"BMJ"},{"key":"B37","volume-title":"Genetics","year":"2024"},{"key":"B38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1191\/1471082x02st033oa","article-title":"Assessing uncertainty about parameter estimates with incomplete repeated ordinal data","volume":"2","author":"Verzilli","year":"2002","journal-title":"Stat. Model."},{"key":"B44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ajhg.2017.06.005","article-title":"10 Years of GWAS discovery: biology, function, and translation","volume":"101","author":"Visscher","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"160018","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR Guiding Principles for scientific data management and stewardship","volume":"3","author":"Wilkinson","year":"2016","journal-title":"Sci. Data"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1093\/bioinformatics\/btab427","article-title":"TIGA: target illumination GWAS analytics","volume":"37","author":"Yang","year":"2021","journal-title":"Bioinformatics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1378\/chest.06-2450","article-title":"Registering a clinical trial in ClinicalTrials.gov","volume":"131","author":"Zarin","year":"2007","journal-title":"Chest"},{"key":"B43","doi-asserted-by":"publisher","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","article-title":"The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods","volume":"52","author":"Zdrazil","year":"2024","journal-title":"Nucleic acids Res."}],"container-title":["Frontiers in Bioinformatics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2025.1579865\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T01:24:09Z","timestamp":1749432249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2025.1579865\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":43,"alternative-id":["10.3389\/fbinf.2025.1579865"],"URL":"https:\/\/doi.org\/10.3389\/fbinf.2025.1579865","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.23.25321034","asserted-by":"object"}]},"ISSN":["2673-7647"],"issn-type":[{"value":"2673-7647","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"article-number":"1579865"}}